Trial Title:
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
NCT ID:
NCT05907447
Condition:
Lymphoma
Extranodal Lymphoma
Diffuse Large B Cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Marginal Zone Lymphoma
Mucosa-Associated Lymphoid Tissue Lymphoma
NK/T-Cell Lymphoma, Nasal and Nasal-Type
Intravascular Large B-Cell Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, B-Cell
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Large-Cell, Anaplastic
Immunoblastic Lymphadenopathy
Conditions: Keywords:
LYMPHOMA
EXTRANODAL
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
No interventions need to be specified for this study
Description:
No interventions need to be specified for this study
Summary:
The aim of this study is to retrospectively collect clinical information on patients with
extranodal or rare lymphomas, and to explore the best treatment strategy for these
lymphomas in the real-world population.
Detailed description:
Lymphoma is a highly common malignant tumor in Asia. For specific extra-abdominal sites
or rare pathological subtypes of lymphoma, traditional chemotherapy protocols often
cannot provide satisfactory results for patients. This study aims to retrospectively
collect clinical information on patients with extranodal lymphoma or rare pathological
subtype lymphoma, including the distribution of involved sites, clinical and molecular
characteristics of different lymphoma subtypes, clinical treatment protocols, and
prognosis, to explore the best treatment strategy for these lymphomas in the real-world
population.
Criteria for eligibility:
Study pop:
Adult patients with histologically confirmed diagnosis of non-Hodgkin lymphoma with
extranodal involvement or non-Hodgkin lymphoma of rare pathological types attending
participating centres.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Age ≥ 18 years (including 18 years old).
2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement,
whether it is primary, secondary, or cannot be determined; Or patients newly
diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL,
SMZL, ALCL, AITL, MALTL.
3. Patients who have received systematic clinical treatment.
4. Patients with measurable lesions, at least containing one effective evaluation of
efficacy.
Exclusion Criteria:
1. Patients who only receive supportive treatment.
2. Patients who cannot obtain effective evaluation data of efficacy.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Address:
City:
Shanghai
Country:
China
Contact:
Last name:
Weili Zhao
Email:
zwl_trial@163.com
Start date:
July 1, 2023
Completion date:
October 1, 2024
Lead sponsor:
Agency:
Ruijin Hospital
Agency class:
Other
Collaborator:
Agency:
Nanfang Hospital, Southern Medical University
Agency class:
Other
Collaborator:
Agency:
Fujian Medical University Union Hospital
Agency class:
Other
Collaborator:
Agency:
Peking University Third Hospital
Agency class:
Other
Collaborator:
Agency:
Peking University People's Hospital
Agency class:
Other
Collaborator:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Collaborator:
Agency:
Beijing Hospital
Agency class:
Other
Collaborator:
Agency:
The Second Affiliated Hospital of Dalian Medical University
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Guangzhou Medical University
Agency class:
Other
Collaborator:
Agency:
Henan Provincial People's Hospital
Agency class:
Other
Collaborator:
Agency:
Hunan Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
Henan Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
The First Hospital of Jilin University
Agency class:
Other
Collaborator:
Agency:
Wuhan Union Hospital, China
Agency class:
Other
Collaborator:
Agency:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Agency class:
Other
Collaborator:
Agency:
Affiliated Hospital of Nantong University
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Xiamen University
Agency class:
Other
Collaborator:
Agency:
Shandong Provincial Hospital
Agency class:
Other
Collaborator:
Agency:
Shanxi Province Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
RenJi Hospital
Agency class:
Other
Collaborator:
Agency:
Beijing Friendship Hospital
Agency class:
Other
Collaborator:
Agency:
West China Hospital
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Soochow University
Agency class:
Other
Collaborator:
Agency:
Tongji Hospital
Agency class:
Other
Collaborator:
Agency:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Agency class:
Other
Collaborator:
Agency:
Sun Yat-sen University
Agency class:
Other
Collaborator:
Agency:
Chongqing University Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
Anhui Provincial Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
The General Hospital of Northern Theater Command
Agency class:
Other
Collaborator:
Agency:
Qilu Hospital of Shandong University
Agency class:
Other
Collaborator:
Agency:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Agency class:
Other
Collaborator:
Agency:
The Affiliated Hospital Of Guizhou Medical University
Agency class:
Other
Collaborator:
Agency:
Wuhan TongJi Hospital
Agency class:
Other
Collaborator:
Agency:
General Hospital of Ningxia Medical University
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Nanchang University
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital with Nanjing Medical University
Agency class:
Other
Collaborator:
Agency:
Anshan Central Hospital
Agency class:
Other
Collaborator:
Agency:
Hainan Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
Fifth Affiliated Hospital of Guangzhou Medical University
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Anhui Medical University
Agency class:
Other
Collaborator:
Agency:
The Affiliated Hospital of Xuzhou Medical University
Agency class:
Other
Collaborator:
Agency:
First Affiliated Hospital of Harbin Medical University
Agency class:
Other
Collaborator:
Agency:
Zhujiang Hospital
Agency class:
Other
Source:
Ruijin Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05907447
